Chronix Biomedical to Launch Cancer Disease Tracking Service

Chronix Biomedical will introduce a novel disease monitoring and detection service for the cancer research community at the 2010 ASCO Annual Meeting. This laboratory-based testing service, known as the ‘For Investigational Use Only,’ utilizes the breakthrough approach of Chronix. This approach, namely the Apoptotic DNA Blood Test of Chronix, is able to analyze the apoptotic DNA from the dying or dead cells for identifying and monitoring ongoing variations related to particular types of cancers and various chronic diseases.

Such proprietary blood test technique of Chronix has demonstrated accurate disease detection and better speed in comparison with other testing methodologies. The Chronix test is also able to offer information useful for choosing the best treatment for a patient.

This service will be provided initially to cancer researchers from the pharmaceutical research and medical oncology domain. This laboratory-enabled testing service will empower the cancer researchers to track their patients’ disease status with a high degree of specificity and sensitivity by utilizing a simple blood test, according to Chronix’s Chief Executive Officer Howard Urnovitz, Ph.D. besides promising prostate and breast cancer data, scientists will also be able to develop assays for other types of cancers. He added that this service would assist researchers to expand the database that would support utilization of assays for ongoing patient care.

An increasing number of peers, who have reviewed the data, have demonstrated that the Chronix blood test is able to detect cancer in the initial phases.

At ASCO, Chronix will provide data from a study that analyzed 575 patients, where it had detected breast and prostate cancer accurately, with 100% specificity and 92% sensitivity. This was achieved through the use of a distinctive algorithm created for sensing and identifying disease related DNA fragments present in the apoptotic cells’s blood.

Chronix will be presenting on the prostate and breast cancer study results during an oral ASCO session on June 7.